Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2002
Business Overview: GSK is a major global healthcare group engaged in the discovery, development, manufacture, and marketing of pharmaceuticals (prescription medicines and vaccines) and consumer healthcare products (OTC medicines, oral care, and nutritional healthcare). The company operates in over 102 countries with products sold in more than 150 countries. The reporting period reflects the third year following the 2000 merger of Glaxo Wellcome and SmithKline Beecham.
Key Financial Metrics (2002)
| Metric | 2002 (£m) | 2001 (£m) | Change (%) |
|---|---|---|---|
| Total Sales | 21,212 | 20,489 | 4% (7% CER*) |
| Trading Profit (Statutory) | 5,662 | 4,697 | 21% (26% CER) |
| Profit Before Taxation (Statutory) | 5,506 | 4,517 | 22% (28% CER) |
| Earnings (Net Income) | 3,915 | 3,053 | 28% (35% CER) |
| Basic EPS | 66.2p | 50.3p | 32% (38% CER) |
| Adjusted Earnings (Business Performance) | 4,627 | 4,383 | 6% (11% CER) |
| Adjusted EPS | 78.3p | 72.3p | 8% (13% CER) |
| Free Cash Flow | 5,387 | 4,599 | 17% |
| Net Debt | (2,335) | (2,101) | 11% increase |
| Gearing Ratio | 24% | 20% | N/A |
*CER = Constant Exchange Rate growth, excluding currency fluctuations.
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 4% at actual exchange rates and 7% at constant exchange rates (CER). Pharmaceutical sales grew 8% (CER), driven by new products which now represent 27% of total pharmaceutical sales. Consumer Healthcare sales grew 2% (CER).
- Profitability: Statutory trading profit grew 21% (26% CER), outpacing sales growth due to cost savings from merger integration and manufacturing restructuring. Business performance trading profit grew 15% (CER), with margins improving by 2.1 percentage points to 31.6%.
- Generic Competition: Significant impact from generic competition in the USA for Augmentin (sales down 20% in the US) and Ceftin (sales down 80% in the US). This was partially offset by the launch of new formulations (Augmentin XR and ES).
- Product Performance: Seretide/Advair sales grew 96% to £1.6 billion. Trizivir (HIV) grew 95%. Wellbutrin grew 42%. Paxil sales grew 15% globally despite patent challenges.
- Share Buy-back: The company spent £2,220 million purchasing its own shares for cancellation, contributing to the increase in net debt and the decrease in equity shareholders' funds.
Guidance, Outlook, and Risks
- 2003 Guidance: Management forecasts high single-digit percentage growth in business performance earnings per share at constant exchange rates. This guidance assumes no generic competition to Paxil in the USA. If a generic launch becomes imminent, guidance will be reassessed.
- Restructuring Savings: The company is on track to deliver total annual merger and manufacturing restructuring savings of at least £1.8 billion by the end of 2003.
- Key Risks:
- Patent Challenges: Ongoing litigation regarding patents for Augmentin, Paxil, Wellbutrin, and Zofran. A federal judge ruled Augmentin patents invalid in the US (appeal pending); a judge ruled Paxil patents valid but not infringed by Apotex (appeal pending).
- Product Liability: Significant exposure to litigation regarding Baycol (co-promoted with Bayer), Paxil (addiction/withdrawal claims), and Lotronex (withdrawn product).
- Regulatory & Pricing: Pressure on pharmaceutical pricing in Europe and the US, and potential changes to Medicare reimbursement.
- Transfer Pricing: Significant open issues with the US IRS regarding transfer pricing, particularly related to Zantac.
Important Facts for Investor Verification
- Patent Litigation Outcomes: Monitor the status of appeals regarding Augmentin and Paxil patents, as a loss could trigger immediate generic competition and significant revenue erosion.
- Generic Impact on Augmentin: Verify the extent of sales recovery from new formulations (XR/ES) versus the loss of market share to generics in the US.
- US Tax Dispute: Review the status of the transfer pricing dispute with the US IRS, as the potential liability is described as substantial and could materially impact future earnings.
- Product Liability Provisions: Assess the adequacy of provisions for Baycol and Paxil litigation, noting that the company has accepted greater uninsured exposure to contain insurance costs.
- Share Buy-back Execution: Confirm the progress of the new £4 billion share buy-back programme announced in October 2002 and its impact on future EPS.